Diabetes mellitus
Conditions
Interventions
 
N/A 
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age 50 years or older - Understanding of the Dutch language - For the diabetes subgroups: participation in UCC-SMART and diabetes mellitus, defined as a self-reported history of diabetes, use of oral glucose-lowering medication or insulin, or a fasting serum glucose concentration of >=7 mmol/L at study inclusion. o Type 1 diabetes: diabetes in individuals who immediately needed insulin at onset and absence of oral glucose lowering medication. o Type 2 diabetes: diabetes in individuals with a self-reported history of type 2 diabetes, with a referral diagnosis of type 2 diabetes, or use or oral glucose-lowering medication - For controls, we will include age- and sex-matched controls without diabetes who have not been included in UCC-SMART.
Exclusion criteria
Exclusion criteria: - Diabetes other than type 1 or type 2, e.g., maturity onset diabetes of youth, gestational diabetes or diabetes due to pancreatic disease - Prediabetes - Any general contra-indication for brain MRI, i.e., metallic objects in or around the body (e.g., cardiac implantable electronic device such as pacemakers and implantable cardioverter defibrillators), claustrophobia or pregnancy - Other major neurological or psychiatric conditions affecting the brain and interfering with the study design, e.g., multiple sclerosis, epilepsy, Parkinson*s disease, prior stroke or vascular dementia - Other factors that may limit the interpretation of the study results, i.e., uncontrolled hypertension (defined as systolic or diastolic blood pressure >160/110 mmHg with or without use of antihypertensive medication), current smoking or BMI >40 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measures are 7T brain MRI microvascular markers, i.e., microvascular reactivity to a visual stimulus, microvascular reactivity to hypercapnia and microvascular blood flow velocity and pulsatility. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures are 3T brain MRI diffusion tension imaging (a sensitive marker of brain parenchyma damage) and cognitive performance (domain-specific cognitive test battery). | — |
Countries
Netherlands
Contacts
Public ContactT.T. Sloten
Universitair Medisch Centrum Utrecht
Outcome results
None listed